CompletedPhase 4

Dexmedetomidine Versus Ketamine-midazolam Sedation in Awake Fiberoptic Intubation in Suspected Difficult Airway

Egypt34 participantsStarted 2023-05-15

Plain-language summary

The goal of this clinical trial is to obtain the optimal patient's comfort and cooperation during awake fiberoptic intubation with prototype device. The main question it aims to answer is: Which drug provides better sedative effect during awake fiberoptic intubation, dexmedetomidine or ketamine- midazolam combination with prototype supraglottic topical anaesthesia device?

Who can participate

Age range21 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient consent * Age 21 to 60 years * Both male and female * ASA I and ASA II * BMI : ((18.5 - 35 kg/ m2 )), * Patient scheduled to undergo elective surgeries under general anesthesia. * Patient with suspected difficult airway. Exclusion Criteria: * Sever chronic disease (cardiovascular, respiratory, renal and hepatic). * Coagulopathies * Mental retarted or psychiatric disorder.

What they're measuring

Patient tolerance

Timeframe: During the procedure of awake fiberoptic intubation

Trial details

NCT IDNCT06946212

SponsorZagazig University

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2024-01-20

View on ClinicalTrials.gov More Awake Fiberoptic Intubation trials